Horizon Therapeutics Public Limited Company (HZNP) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - General secteur d'activité. Le siège social de l'entreprise est situé à Dublin, Ireland. Le PDG actuel est Timothy P. Walbert.
HZNP a date d'introduction en bourse 2011-07-28, 2,190 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $26.6B.
Horizon Therapeutics Public Limited Company is a biotechnology company focused on discovering, developing, and commercializing medicines for rare, autoimmune, and severe inflammatory diseases. The company operates through two segments—Orphan and Inflammation—with a portfolio of 12 medicines spanning rare diseases, gout, ophthalmology, and inflammatory conditions. Its marketed products include TEPEZZA for thyroid eye disease, KRYSTEXXA for gout, RAVICTI and PROCYSBI for rare metabolic disorders, ACTIMMUNE for chronic granulomatous disease, and several anti-inflammatory and pain management therapies such as PENNSAID, DUEXIS, RAYOS, and VIMOVO. Founded in 2005 and headquartered in Dublin, Ireland, Horizon maintains research and commercial operations across multiple locations in the United States, Germany, and internationally through strategic collaborations with biotechnology partners.
